Financial Comparison: Braskem (BAK) and Enzymotec (ENZY)

Braskem (NYSE: BAK) and Enzymotec (NASDAQ:ENZY) are both oils/energy companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Valuation & Earnings

This table compares Braskem and Enzymotec’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Braskem $13,743.20 0.90 -$117.96 N/A N/A
Enzymotec $47.70 5.80 -$2.92 ($0.29) -40.69

Enzymotec has higher revenue, but lower earnings than Braskem.

Analyst Ratings

This is a breakdown of recent ratings for Braskem and Enzymotec, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Braskem 0 0 2 0 3.00
Enzymotec 0 2 0 0 2.00

Braskem presently has a consensus price target of $22.00, indicating a potential downside of 29.42%. Enzymotec has a consensus price target of $11.75, indicating a potential downside of 0.42%. Given Enzymotec’s higher probable upside, analysts plainly believe Enzymotec is more favorable than Braskem.


This table compares Braskem and Enzymotec’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Braskem 3.38% 34.93% 2.74%
Enzymotec -14.52% -3.88% -3.58%

Institutional and Insider Ownership

0.7% of Braskem shares are owned by institutional investors. Comparatively, 27.2% of Enzymotec shares are owned by institutional investors. 0.0% of Braskem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Braskem has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Enzymotec has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.


Braskem beats Enzymotec on 7 of the 12 factors compared between the two stocks.

Braskem Company Profile

Braskem S.A. produces thermoplastic resins. The Company’s segments are Basic petrochemicals, Polyolefins, Vinyls, the United States and Europe, and Chemical distribution. It is also engaged in the import and export of chemicals, petrochemicals and fuels, the production, supply and sale of utilities such as steam, water, compressed air, industrial gases, the provision of industrial services, and the production, supply and sale of electric energy. It also invests in other companies, either as a partner or as shareholder. It operates over 40 industrial units, over 30 of which are located in the Brazilian states of Alagoas, Bahia, Rio de Janeiro, Rio Grande do Sul and Sao Paulo; over five are located in the United States, in the states of Pennsylvania, Texas and West Virginia, and over two are located in Germany, in the cities of Wesseling and Schkopau. These units produce thermoplastic resins–polyethylene, polypropylene and polyvinyl chloride, as well as basic petrochemicals.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

What are top analysts saying about Braskem S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Braskem S.A. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit